Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
PISCES I: Precision Implemented Smoking Cessation Evaluation Study
Sponsor: M.D. Anderson Cancer Center
A PHASE4 clinical study on Cigarette Smoking-Related Carcinoma, this trial is actively recruiting participants. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 11 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Nov 2025 — Present [monthly]
Recruiting PHASE4
-
May 2025 — Nov 2025 [monthly]
Recruiting PHASE4
-
Oct 2024 — May 2025 [monthly]
Recruiting PHASE4
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
▶ Show 6 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE4
-
Nov 2023 — Apr 2024 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Feb 2023 — Nov 2023 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Recruiting PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE4
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .